EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neuroprotective Riluzole-Releasing Electrospun Implants for Spinal Cord Injury

Mathilde M Ullrich, Bhavana Pulipaka, Jing Yin, Jana Hlinková, Fangyuan Zhang, Michael W Chan iD, Fergal J O'Brien, Adrian Dervan, Karolina Dziemidowicz iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.4c01270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Mathilde M Ullrich und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, U.K. Hauptthemen laut MEDLINE: Riluzole, Spinal Cord Injuries, Neuroprotective Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council, Science Foundation Ireland, Ministerstvo ?kolstv?, Ml?de?e a Telov?chovy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spinal cord injury (SCI) results in paralysis, driven partly by widespread glutamate-induced secondary excitotoxic neuronal cell death in and around the injury site. While there is no curative treatment, the standard of care often requires interventive decompression surgery and repair of the damaged dura mater close to the injury locus using dural substitutes. Such intervention provides an opportunity for early and local delivery of therapeutics directly to the injured cord via a drug-loaded synthetic dural substitute for localized pharmacological therapy. Riluzole, a glutamate-release inhibitor, has shown neuroprotective potential in patients with traumatic SCI, and therefore, this study aimed to develop an electrospun riluzole-loaded synthetic dural substitute patch suitable for the treatment of glutamate-induced injury in neurons. A glutamate-induced excitotoxicity was optimized in SH-SY5Y cells by exploring the effect of glutamate concentration and exposure duration. The most effective timing for administering riluzole was found to be at the onset of glutamate release as this helped to limit extended periods of glutamate-induced excitotoxic cell death. Riluzole-loaded patches were prepared by using blend electrospinning. Physicochemical characterization of the patches showed the successful encapsulation of riluzole within polycaprolactone fibers. A drug release study showed an initial burst release of riluzole within the first 24 h, followed by a sustained release of the drug over 52 days to up to approximately 400 μg released for the highest loading of riluzole within fiber patches. Finally, riluzole eluted from electrospun fibers remained pharmacologically active and was capable of counteracting glutamate-induced excitotoxicity in SH-SY5Y cells, suggesting the clinical potential of riluzole-loaded dural substitutes in counteracting the effects of secondary injury in the injured spinal cord.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RiluzoleSpinal Cord InjuriesNeuroprotective AgentsHumansGlutamic AcidCell Line, TumorNeuronsAnimalsDrug LiberationDrug ImplantsPolyesters

Stichwörter der Autor:innen

SH-SY5Yelectrospinningglutamate-induced excitotoxicityriluzolespinal cord injury

Substanzen

RiluzoleNeuroprotective AgentsGlutamic AcidDrug ImplantsPolyesters

Autor:innen und Institutionen

  • Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, U.K.
  • Tissue Engineering Research Group, Department of Anatomy & Regenerative Medicine, Royal College of Surgeons in Ireland (RCSI), 123 St Stephens Green, Dublin 2 D02 YN77, Ireland.
  • Department of Tissue Engineering, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 142 20, Czechia.
  • Department of Biomaterials, Faculty of Dentistry, University of Oslo, Geitmyrsveien 69/71, PB 1142 Blindern, Oslo 0317, Norway.
  • Advanced Materials and Bioengineering Research Centre (AMBER), Trinity College Dublin, College Green, Dublin 2 D02 W9K7, Ireland.

ORCID-Profile: Michael W Chan, Karolina Dziemidowicz

Förderung

  • Engineering and Physical Sciences Research Council
  • Science Foundation Ireland
  • Ministerstvo ?kolstv?, Ml?de?e a Telov?chovy
  • Irish Rugby Football Union

Zitieren

APA

Ullrich, M. M., Pulipaka, B., Yin, J., Hlinková, J., Zhang, F., Chan, M. W., O'Brien, F. J., Dervan, A., & Dziemidowicz, K. (2025). Neuroprotective Riluzole-Releasing Electrospun Implants for Spinal Cord Injury. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01270

Vancouver

Ullrich MM, Pulipaka B, Yin J, Hlinková J, Zhang F, Chan MW, et al. Neuroprotective Riluzole-Releasing Electrospun Implants for Spinal Cord Injury. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01270

BibTeX
@article{Ullrich2025,
  author = {Ullrich, Mathilde M and Pulipaka, Bhavana and Yin, Jing and Hlinková, Jana and Zhang, Fangyuan and Chan, Michael W and O'Brien, Fergal J and Dervan, Adrian and Dziemidowicz, Karolina},
  title = {Neuroprotective Riluzole-Releasing Electrospun Implants for Spinal Cord Injury},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.4c01270}
}
Kostenlos starten →